UGC Approved Journal no 63975(19)

ISSN: 2349-5162 | ESTD Year : 2014
Call for Paper
Volume 11 | Issue 5 | May 2024

JETIREXPLORE- Search Thousands of research papers



WhatsApp Contact
Click Here

Published in:

Volume 11 Issue 1
January-2024
eISSN: 2349-5162

UGC and ISSN approved 7.95 impact factor UGC Approved Journal no 63975

7.95 impact factor calculated by Google scholar

Unique Identifier

Published Paper ID:
JETIR2401679


Registration ID:
531276

Page Number

g661-g674

Share This Article


Jetir RMS

Title

Management of Rheumatoid Arthritis

Authors

Abstract

The primary characteristic of rheumatoid arthritis, an inflammatory autoimmune illness, is synovitis. Extra articular organ involvement, interstitial pneumonia, and clinical symptoms such as pain, edema, stiffness in many joints, fever, and malaise are also present. Joint destruction follows in the early stages with rapid advancement. In addition to the appearance of persistent physical impairment, deformed joints are noted. Early sickness diagnosis and treatment are so essential. In palliative care, glucocorticoids and anti-inflammatory pharmaceuticals were employed; however, disease-modifying anti rheumatic drugs (DMARDs) are currently used to control the disease's progression and decrease immunological abnormalities. DMARDs are classified into multiple groups, such as targeted synthetic DMARDs, conventional synthetic DMARDs, and biologic DMARDs. Now, when these drugs are used as prescribed, every patient's therapeutic objective might be remission. By maintaining remission, these drugs have also been shown to prevent joint deterioration and physical dysfunction over an extended period of time. Pathological mechanism-based treatment methods are currently being employed to treat a variety of autoimmune inflammatory illnesses, thanks to the advent of molecularly targeted medicines. Future medical advancements are expected to bring in precision medicine, therapeutic techniques aimed at medication holidays or cures, and safer and more effective treatments.

Key Words

DMARD, biological, diagnosis, treatment, and rheumatoid arthritis

Cite This Article

"Management of Rheumatoid Arthritis", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.11, Issue 1, page no.g661-g674, January-2024, Available :http://www.jetir.org/papers/JETIR2401679.pdf

ISSN


2349-5162 | Impact Factor 7.95 Calculate by Google Scholar

An International Scholarly Open Access Journal, Peer-Reviewed, Refereed Journal Impact Factor 7.95 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage Journal Indexing in All Major Database & Metadata, Citation Generator

Cite This Article

"Management of Rheumatoid Arthritis", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.11, Issue 1, page no. ppg661-g674, January-2024, Available at : http://www.jetir.org/papers/JETIR2401679.pdf

Publication Details

Published Paper ID: JETIR2401679
Registration ID: 531276
Published In: Volume 11 | Issue 1 | Year January-2024
DOI (Digital Object Identifier):
Page No: g661-g674
Country: greater Noida, UP, India .
Area: Pharmacy
ISSN Number: 2349-5162
Publisher: IJ Publication


Preview This Article


Downlaod

Click here for Article Preview

Download PDF

Downloads

00046

Print This Page

Current Call For Paper

Jetir RMS